Omega Therapeutics Stock (NASDAQ:OMGA)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$0.76

52W Range

$0.75 - $6.30

50D Avg

$1.17

200D Avg

$2.17

Market Cap

$43.75M

Avg Vol (3M)

$268.67K

Beta

1.84

Div Yield

-

OMGA Company Profile


Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

93

IPO Date

Jul 30, 2021

Website

OMGA Performance


OMGA Financial Summary


Dec 23Dec 22Dec 21
Revenue$3.09M$2.07M$144.00K
Operating Income$-100.26M$-102.77M$-66.03M
Net Income$-97.43M$-102.64M$-69.16M
EBITDA$-100.26M$-102.77M$-64.67M
Basic EPS$-1.80$-3.18$-3.09
Diluted EPS$-1.80$-3.18$-3.09

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
OLMAOlema Pharmaceuticals, Inc.
PMVPPMV Pharmaceuticals, Inc.
CNTACentessa Pharmaceuticals plc
LRMRLarimar Therapeutics, Inc.
MLYSMineralys Therapeutics, Inc.
CVKDCadrenal Therapeutics, Inc. Common Stock
AVTEAerovate Therapeutics, Inc.
OBIOOrchestra BioMed Holdings, Inc.
MLTXMoonLake Immunotherapeutics
MNOVMediciNova, Inc.
PHVSPharvaris N.V.
GPCRStructure Therapeutics Inc.
PEPGPepGen Inc.
NVCTNuvectis Pharma, Inc.
ELVNEnliven Therapeutics, Inc.
CMPXCompass Therapeutics, Inc.
ELYMEliem Therapeutics, Inc.